Sign In
Buy TAK
$17.09
-0.160 (-0.93%)
At Close: Jul 31, 2026
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
06:38pm, Thursday, 04'th Dec 2025
SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed
Boston Partners Has $1.64 Million Stock Holdings in Takeda Pharmaceutical Co. $TAK
04:12am, Monday, 01'st Dec 2025
Boston Partners decreased its position in shares of Takeda Pharmaceutical Co. (NYSE: TAK) by 20.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Co
AlphaCore Capital LLC Takes $192,000 Position in Takeda Pharmaceutical Co. $TAK
03:09am, Wednesday, 26'th Nov 2025
AlphaCore Capital LLC acquired a new position in shares of Takeda Pharmaceutical Co. (NYSE: TAK) during the undefined quarter, according to the company in its most recent filing with the Securities an
US FDA investigates death tied to Takeda's blood disorder drug
12:00pm, Friday, 21'st Nov 2025
The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder drug, the health regulator said on Friday.
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year e
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079
New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
07:00am, Monday, 03'rd Nov 2025
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial
10,225 Shares in Takeda Pharmaceutical Co. $TAK Purchased by Focus Partners Advisor Solutions LLC
03:27am, Sunday, 02'nd Nov 2025
Focus Partners Advisor Solutions LLC acquired a new position in shares of Takeda Pharmaceutical Co. (NYSE: TAK) in the second quarter, according to its most recent Form 13F filing with the Securities
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
04:16pm, Thursday, 30'th Oct 2025
Takeda Pharmaceutical Company Limited ( TAK ) Q2 2026 Earnings Call October 30, 2025 6:00 AM EDT Company Participants Christopher David O'Reilly - Global Head of Investor Relations & Global Finance Ch
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges
09:13am, Thursday, 30'th Oct 2025
Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a second-quarter 2025 adjusted net profit of 201.6 billion Japanese yen (approximately $1.31 billion).
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. T
Yousif Capital Management LLC Has $501,000 Stock Holdings in Takeda Pharmaceutical Co. $TAK
03:48am, Friday, 24'th Oct 2025
Yousif Capital Management LLC lifted its holdings in Takeda Pharmaceutical Co. (NYSE: TAK) by 8.5% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 32,394
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules October 22, 2025 9:00 AM EDT Company Participants Zheng
China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion
12:43am, Wednesday, 22'nd Oct 2025
The tie-up is the latest between Chinese companies and international pharma majors looking to expand their global reach and tap promising drug pipelines developing in China.
China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda
08:39pm, Tuesday, 21'st Oct 2025
China's Innovent Biologics said on Wednesday it had signed an $11.4 billion deal with Japan's Takeda Pharmaceutical Co to accelerate the development of its immuno-oncology and antibody-drug conjugate
